Patent ID: 11939637
Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 10:
11. The method according to claim 1, wherein the agent comprises a checkpoint inhibitor,
(a) wherein the checkpoint inhibitor is an inhibitor of the programmed death-1 (PD-1) pathway,
wherein the inhibitor of the PD-1 pathway is an anti-PD1 antibody, and wherein the inhibitor of the PD-1 pathway is nivolumab; or
(b) wherein the checkpoint inhibitor is an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibody, and
wherein the anti-CTLA4 antibody is ipilimumab or tremelimumab.